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Does Gadolinium-Based Angiography Protect
Against Contrast-Induced Nephropathy?:
A Systematic Review of the Literature
Thomas F. Boyden, MD and Hitinder S. Gurm,* MD
We evaluated the incidence of contrast-induced nephropathy (CIN) in patients exposed
to gadolinium for diagnostic or therapeutic procedures. Background: CIN with iodin-
ated contrast agents is a leading cause of acute renal failure. Gadolinium is often used
as an alternative to iodinated contrast in patients at increased risk of CIN. The safety
of gadolinium in patients at increased risk of CIN has not been established. Methods
and Results: The authors performed a systematic review by searching MEDLINE, ISI
Web of Knowledge, Current Contents, Embase, and the Cochrane Central Register of
Controlled Trials to identify relevant studies evaluating gadolinium and its associated
incidence of CIN. They identified 17 studies that reported both favorable and negative
results with regard to the association of gadolinium and CIN. The differences in the
results appeared to be dose related. When gadolinium was used in doses of 0.4 mmol/
kg or higher, there appeared to be an increased incidence of ARF particularly in
patients with preexisting renal insufficiency. Conclusions: Although the evidence base
is limited, gadolinium does not appear to be safer than iodinated contrast in patients
at risk of CIN. Given the lack of randomized data to support its safety, gadolinium in
lieu of iso-osmolar iodinated contrast cannot be advocated in patients at high risk of
contrast nephropathy. ' 2008 Wiley-Liss, Inc.
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INTRODUCTION
Diagnostic and therapeutic procedures requiring con-
trast media have risen dramatically over the past two
decades [1,2]. With this increase, the incidence of
contrast-induced nephropathy (CIN) has also risen, and
CIN now stands as the third most common cause of
acute renal failure [3,4]. The incidence of CIN has
been reported to be as high as 10–30% in patients
with preexisting chronic renal insufficiency receiving
intravascular iodinated contrast [2,4–8].
CIN is a major predictor of early and late mortality in
patients undergoing coronary artery interventions [9–11].
Although hydration, pretreatment with N-acetylcysteine,
and use of iso-osmolar contrast have reduced the inci-
dence of CIN [1], it still remains a major concern in
patients scheduled to undergo vascular imaging espe-
cially in those with preexisting renal insufficiency.
Gadolinium has long been used as a contrast medium
in magnetic resonance imaging. As it was originally
believed to be nonnephrotoxic, gadolinium has been
used as a replacement for iodinated contrast in patients
deemed to be at high risk of CIN undergoing vascular
imaging. However, there are conflicting data with respect
to gadolinium’s safety in patients at high risk of CIN
[7,8,12–22]. Although no large randomized trials have
been undertaken to elucidate gadolinium’s safety com-
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pared with iodinated agents, multiple small, randomized
trials as well as prospective observational and retrospec-
tive studies have examined this relationship. We per-
formed a systematic review to assess the data evaluating
gadolinium’s safety when used as a contrast medium for
patients undergoing vascular angiography.
METHODS
We performed our systematic review using guidelines
from the Cochrane Collaboration. A computerized search
was performed to identify relevant articles (through De-
cember 31, 2006) in the MEDLINE, ISI Web of Knowl-
edge, Current Contents, Embase, and the Cochrane Cen-
tral Register of Controlled Trials. We combined exploded
medical subject headings and keyword searches for gado-
linium, CIN, nephropathy and angiography. Published
meta-analyses, review articles, case reports and editorials
were reviewed for potential trials of interest.
A study was included if gadolinium was a contrast
agent of study and included outcome data on renal func-
tion before and after administration of this contrast agent.
Information was abstracted using a standardized form.
Abstracted information included patient characteristics
(mean age, chronic renal insufficiency, and diabetes mel-
litus), amount of gadolinium used during procedure, base-
line creatinine, postprocedure creatinine, and inclusion
and exclusion criteria for enrollment if provided.
We selected trials based on evaluation of gadolinium
in human subjects. These included randomized and
observational studies (both prospective and retrospec-
tive). The primary outcomes of interest included post-
procedural CIN. No single definition of CIN exists
among the various studies examined in this review. Cri-
teria used to define CIN ranged from a rise in creatinine
>0.3–0.5 mg/dL within 48 hr of contrast administration
to a decrease in glomerular filtration rate >50%.
RESULTS
Our search identified 17 relevant studies from 1996
through 2007: four randomized controlled trials, nine
prospective observational studies, and four retrospec-
tive analyses. Primary endpoints differed among each
study. The amount of gadolinium used also varied
based on procedural characteristics among the studies
included in this analysis.
Baseline patient characteristics were similar among
each trial and included patients with chronic renal insuf-
ficiency and diabetes mellitus. Follow up was similar in
each study; however, outcome data based on preexisting
comorbidities prior to procedure were not reported.
In each trial, patients received intravenous fluid
hydration prior to and after their procedure. Type of
intravenous fluid used was at the discretion of the
individual investigators. Acetylcysteine was also
administered at the discretion of the investigator and
was predominately used in patients with preexisting re-
nal insufficiency.
The 17 studies in our review reported both favorable
and negative results with regard to the association of
gadolinium and CIN [7,8,12–22]. The differences in
the results appeared to be possibly dose related with
an increased incidence of ARF when gadolinium was
used in doses of 0.4 mmol/kg or higher. As each study
in this systematic review varied in its design and out-
comes of interest, each study is described below with
total dose of gadolinium administration and resultant
change in kidney function. See Tables I and II for
details with respect to preprocedure and postprocedure
kidney function and dose of gadolinium administered.
Randomized Trials
Of the four randomized trials included in this
review, one examined the effects of gadolinium at
high doses, defined in this review as 0.4 mmol/kg,
while three reported outcomes with gadolinium used at
low doses, defined as <0.4 mmol/kg. In only two of
these trials was gadolinium administration compared to
iso-osmolar contrast media administration.
Randomized Comparison of Gadolinium and
Iodinated Contrast
In the high dose trial, Erley et al. examined patients
with renal insufficiency undergoing digital subtraction
angiography [17]. Ten patients received 0.57 6 0.17
mmol/kg gadobutrol vs. 11 receiving 0.60 6 0.27
mmol/kg iohexol. Baseline serum creatinine was similar
in both groups with an average of 3.4 6 1.4 mg/dL in
the gadobutrol group and 3.0 6 1.2 mg/dL in the
iohexol group. Mean glomerular filtration rate (GFR)
decreased in both groups at 48-hr follow up and was
not statistically different between the groups (P 5
0.3226). GFR decreased from 31 6 21 to 21 6 21 ml/
min/1.73 m2 in the gadobutrol group vs. 29 6 11 to
19 6 11 ml/min/1.73 m2 in the iohexol group. Five
patients in each group developed contrast media
induced acute renal failure defined as a decrease in
GFR by 50% of baseline within 48 hr of contrast
media administration. Erley et al. data suggest no bene-
fit of using gadolinium in lieu of iso-osmolar contrast.
Spinosa et al. randomly assigned 40 patients under-
going lower extremity arteriography to CO2 alone, io-
dinated contrast media and CO2 or gadolinium and
CO2 [8]. In the seven procedures using CO2 alone,
including two interventions, none of the patients expe-
rienced a rise in serum creatinine greater than 0.5 mg/
dL at 48 hr. Fifteen procedures in 15 patients were
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performed with the use of CO2 and nonionic contrast
media, including six interventions. Of these patients, 6
developed CIN at 48 hr. Of the 20 procedures, includ-
ing 15 interventions, utilizing gadolinium at 0.13–0.40
mmol/kg and CO2, one patient with a baseline creati-
nine of 3.3 mg/dL experienced a serum creatinine
increase greater than 0.5 mg/dL at 48 hr. This patient
received a total dose of 70 mL of gadodiamide (0.3
mmol/kg). The authors concluded that gadolinium,
when used in small volumes, provided a statistically
significant (P 5 0.03) benefit with respect to renal
function when compared to nonionic contrast media.
Furthermore, the authors determined the gadolinium-
based images to be inferior to those obtained using
nonionic contrast media.
High Dose Versus Low Dose Gadolinium
Studies comparing high and low dose gadolinium
administration in patients undergoing MRI have not con-
firmed a dose response with respect to renal safety of
gadolinium. Tombach et al. randomly assigned 21
patients with impaired renal function undergoing mag-
netic resonance imaging for any indication to receive ei-
ther 0.1 mmol/kg or 0.3 mmol/kg of gadolinium [19].
Follow up occurred at 6, 24, 48, and 72 hr following
administration of contrast media. No adverse events
related to the administration of gadobutrol occurred at ei-
ther dose during follow up. No patients developed acute
renal failure or anuria and none required hemodialysis.
In a similar trial, Haustein et al. randomly assigned
199 patients undergoing magnetic resonance imaging
of the central nervous system to receive either 0.1 or
0.3 mmol/kg gadopentate [14]. Eight adverse events
occurred in the group assigned to receive 0.1 mmol/kg
gadopentate vs. seven adverse events that occurred in
the group that received 0.3 mmol/kg. There were no
cases of acute renal failure reported in either group.
Thus, it is not clear if the different results seen in the
two randomized results comparing iodinated constrast
to gadolinium are secondary to use of a lower dose.
Prospective Analyses
Of the nine prospective analyses identified for this
review, four reported effects of gadolinium on kidney
function when used at high doses. Briguori et al.
examined 25 patients with CRI undergoing coronary
artery procedures [20]. Gadolinium chelates were
diluted 3:1 with iodixanol and compared to a control
group of 32 patients with CRI selected from a database
who had received iodinated iso-osmolality contrast
agent. CIN occurred in 7 of 25 patients receiving the
gadolinium chelate dilution vs. 2 of 32 that received
the iodinated contrast agent alone (P 5 0.034). Hemo-
dialysis was required in two patients in the gadolin-
ium-based group vs. none in the iodinated-based group.
This was not statistically significant (P 5 0.19).
Ailawadi et al. performed renal arteriography in 21
patients with a baseline creatinine of 3.0 mg/dL [16].
In 25 procedures performed using 124 6 74 mL of
gadolinium (ie. 0.4 mmol/kg), no patients suffered
adverse events including acute renal failure, defined as
a rise in serum creatinine greater than 0.3 mg/dL
within 48 hr of contrast administration.
Hammer et al. reported effects of gadolinium in dig-
ital subtraction angiography in patients with renal
insufficiency [26]. Patients received up to but not
exceeding a total of 0.4 mmol/kg of gadolinium. One
patient suffered ARF defined as a rise in creatinine of
>0.5 mg/dL following administration of gadolinium.
However, this patient presented with intraperitoneal
and retroperitoneal hemorrhage following renal biopsy
8 days after renal transplant.
Zeller et al. examined the use of gadodiamide as the
sole contrast agent in patients with iodinated contrast
allergy for digital subtraction angiography and angio-
plasty with or without stent placement [27]. The vol-
ume of gadodiamide administered ranged from 60 to
200 mL (mean volume being 136 6 46 mL). No seri-
ous side effects were noted in this study including no
change in renal function from baseline.
Sancak et al. reported no ARF following administra-
tion of gadolinium when used for digital subtraction
angiography in patients with moderate renal insuffi-
ciency at a dose limited to 0.3 mmol/kg [25]. Simi-
larly, Robert et al. reported only one patient who
developed ARF (defined as a rise in creatinine >0.5
mg/dL) when using gadolinium dosed at a total of
0.15 mmol/kg for digital subtraction angiography
among 39 patients undergoing 42 procedures [24]. The
patient who did develop ARF received both gadolin-
ium and iodine-based contrast agents.
Spinosa et al. examined the use of gadolinium in the
diagnosis and treatment of renal artery stenosis in
patients with preexisting renal insufficiency [12]. Gado-
diamide was administered at 0.3 mmol/kg along with
CO2 intra-arterially in 24 patients for a total of 25 pro-
cedures. Follow up occurred at 24 and 48 hr. In 23 of
the 25 procedures, there was no significant rise in serum
creatinine, defined as an increase in serum creatinine
level greater than 0.5 mg/dL. Of the two patients who
did have a significant increase in serum creatinine, one
underwent renal transplant six years before being en-
rolled in the study and was experiencing an increasing
serum creatinine for two months prior to angiography.
The second patient was found to have bilateral renal ar-
tery stenosis and severe abdominal aortic atherosclero-
sis. This patient underwent angioplasty and renal artery
stenting. It was believed the elevation in serum creati-
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nine was secondary to cholesterol emboli as the patient
developed skin changes consistent with livedo reticula-
ris following the procedure.
Rieger et al. prospectively examined 29 patients
undergoing 32 angiographic procedures including renal,
iliac and lower extremity arteriography as well as
upper extremity and central venous angiography [13].
Total dose of gadopentate administered was
0.34 6 0.06 mmol/kg. Serum creatinine remained sta-
ble after 31 of the 32 procedures. As in the prior
study, the one patient who developed acute renal fail-
ure underwent angioplasty and stent placement for re-
nal artery stenosis and he was noted to have severe
atherosclerosis of the abdominal aorta. As the patient
developed postprocedural skin changes consistent with
livedo reticularis, it was believed this patient suffered
from cholesterol embolism.
Wagner et al. investigated the use of gadolinium for
digital subtraction angiography in patients with contra-
indication to iodinated contrast media [15]. Thirty digi-
tal subtraction angiographies were performed in 22
patients using a 0.5 mol/L solution with an average
volume of 34 6 19 mL administered per patient. No
patients developed CIN.
Retrospective Analyses
In the retrospective studies included in this review,
Reed et al. identified 169 patients with CRI that under-
went diagnostic cardiac catheterization or percutaneous
intervention [23]. They compared a mixture of gadolin-
ium-iodinated contrast to iodinated contrast alone with
CIN as the primary outcome. There were no differen-
ces in the postprocedural serum creatinine levels or
creatinine clearance; however, there was an increased
incidence of dialysis and in-hospital death in the gado-
linium-iodinated contrast mixture group. Total dose of
gadolinium was not specified, but the gadolinium mix-
ture group received 151 6 79 mL of contrast com-
pared to 136 6 72 mL with the iodinated contrast
group.
Sam et al. identified 260 patients that received gado-
linium for magnetic resonance angiography or digital
subtraction angiography [18]. Gadolinium was dosed at
a minimum of 0.25 mmol/kg in all patients. 195 of the
260 patients had a baseline renal insufficiency. Of
those with normal baseline renal function, none devel-
oped acute renal failure. Of those patients with chronic
renal insufficiency, 3 of 153 patients undergoing MRA
and 4 of 42 undergoing DSA developed acute renal
failure. In those who developed ARF, the average dose
of gadolinium was 0.31–0.41 mmol/kg for MRA and
0.27–0.42 mmol/kg for DSA.
Prince et al. performed a retrospective analysis of
patients who underwent aortic, pelvic or renal artery
magnetic resonance angiography with high-dose gado-
linium, 0.2–0.4 mmol/kg, to identify patients who may
have developed CIN [22]. Of the 110 patients identi-
fied that had serum creatinine checked two days prior
to and postprocedure, none had clinically significant
change in renal function or evidence of CIN following
the administration of gadolinium.
Ergun et al. also conducted a retrospective analysis
of 91 patients with stage III or IV renal failure who
underwent MRA [21]. All patients received a total
dose of gadolinium of 0.2 mmol/kg. Eleven of these
patients developed ARF, defined as a serum creatinine
increase of 0.5 mg/dL over baseline after administra-
tion of gadolinium.
DISCUSSION
The key finding of our review is that while observa-
tional data support a low incidence of CIN in patients
with impaired renal function that received gadolinium,
randomized data do not suggest a statistically signifi-
cant benefit over iso-osmolar contrast media when
used in similar doses.
With an ever-increasing number of contrast-based
procedures, the risk of developing CIN remains a seri-
ous concern particularly in patients with underlying re-
nal insufficiency. It has been reported that CIN occurs
in 10–30% of patients with chronic renal insufficiency
that undergo diagnostic angiographic or interventional
procedures with iodinated contrast agents [2,5,7,28,29].
This has led to an incidence of renal replacement ther-
apy that approaches 25% in patients developing CIN,
particularly those who develop oliguria [30,31]. Addi-
tionally, nearly one-third of patients who develop CIN
may never return to their baseline renal function
[28,30].
Multiple risk factors have been identified for CIN
including preexisting renal insufficiency, diabetes mel-
litus, congestive heart failure, volume depletion and
the dose of contrast agent administered [4,6].
Given the high prevalence and significant morbidity
associated with CIN, identification and utilization of a
safe contrast agent is critical for reducing this iatro-
genic adverse outcome. Gadolinium has been consid-
ered safer than iodinated contrast agents with regard to
inducing acute renal failure. As gadolinium has been
increasingly used in clinical practice, it is clear that it
may be more nephrotoxic than originally thought. In
fact, when gadolinium is used in doses that produce
equal attenuation as iodinated contrast agents, use of
gadolinium appears to be associated with a risk of re-
nal dysfunction that is similar to iodinated agents
[32,33].
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While iodinated contrast causes CIN by ischemic
injury to the medulla via the vasoconstrictive response
to the contrast agent, the mechanism by which gadolin-
ium causes nephropathy remains unclear [3,4]. A
recent study of renal biopsy specimens from patients
with gadolinium-associated nephropathy suggests that
gadolinium may induce global sclerosis, tubular atro-
phy, and interstitial fibrosis, thus leading to permanent
renal impairment [3].
Furthermore, multiple sources have documented
nephrogenic systemic fibrosis following the administra-
tion of gadolinium in patients with preexisting renal
failure [34,35]. This condition, which causes thicken-
ing of the skin leading to joint immobility and poten-
tial inability to walk, was first documented in the late
1990s as a fibrotic skin disorder in patients with renal
failure [36,37]. The Centers for Disease Control in the
Morbidity and Mortality Weekly Report for the week
of February 23, 2007, published a case–control analy-
sis submitted by a hospital in St. Louis, MO, which in-
dependently associated the use of gadolinium with this
rare condition.
Our analysis of the available data suggest that gado-
linium provides no clear benefit over iodinated contrast
agents with respect to CIN in patients undergoing
diagnostic angiographic and interventional procedures,
particularly when used in doses approaching equal
attenuation to iodinated contrast media.
Our findings should be interpreted in the context of
the inherent flaws of a systematic review of the litera-
ture that include study selection bias, publication bias
and the inability to adjust for baseline differences
among study subjects. These conclusions are based on
small numbers and may be underpowered to detect a
true difference in the relative renal safety of gadolin-
ium over iodinated contrast.
CONCLUSION
In patients with preexisting renal insufficiency, use
of Gadolinium for vascular angiography appears to be
associated with postprocedural renal dysfunction when
given in doses approaching or exceeding 0.4 mmol/kg.
Given the absence of randomized controlled data to
support its safety, and concerns about serious multi-
organ toxicity, albeit rare, use of gadolinium in lieu of
iso-osmolar iodinated contrast cannot be advocated in
patients at high risk of contrast nephropathy.
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